Introduction {#s1}
============

Vitamin B12 or cobalamin (Cbl) is regarded as the largest and most complex biological 'small molecule'. The molecule consists of a corrin ring chelating a cobalt ion using four equatorial coordinating nitrogen atoms ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). At the α-axial position, the cobalt ion is coordinated by the 5,6-dimethylbenzimidazole (DMBI) base that is linked covalently to the corrin ring. Located at the β-axial position is the sixth coordinating moiety ([@bib21]; [@bib40]). This ligand can vary among cobalamin derivatives and forms a rare organometallic, covalent bond, which offers unique catalytic properties to enzymes that use Cbl as a co-factor. The two most common biological active variants have a methyl or 5'-deoxyadenosyl group at this position, resulting in methyl- and adenosyl-cobalamin (Met-Cbl and Ado-Cbl, respectively). In the industrially produced variant, a cyano-group (CN-Cbl) binds at the β-axial position, and a hydroxy group (OH-Cbl) is present in the degradation product ([@bib21]).

![Structures of cobalamin and cobinamide.\
(**a**) Cobalamin structure, represented in the base-on conformation with the 5',6'-dimethyl-benzimidazole ribonucleotide moiety (α-ligand) coordinating the central cobalt ion. The variable β-ligands are denoted as R in the lower left corner. (**b**) Structure of cobinamide, which lacks the DMBI moiety and has two cyano groups coordinating the cobalt ion from each side of the corrin ring.](elife-35828-fig1){#fig1}

Enzymes that use Cbl as their co-factor catalyze mostly methyl group transfer reactions, or a variety of different radical-mediated reactions ([@bib19]; [@bib21]). The most prominent example for methyl group transfer is MetH, the Cbl-dependent L-methionine synthase, which uses Met-Cbl to transfer a methyl group onto L-homocysteine to produce L-methionine. The methyl group on Cbl is subsequently restored from methyl-folate ([@bib5]; [@bib21]).

The ability to synthesize Cbl de novo is restricted to prokaryotic species in only \~20 genera. Two routes for de novo synthesis have been established (aerobic or anaerobic), each requiring approximately 30 different enzymes, which makes de novo synthesis a very energy consuming process, and could explain why roughly two thirds of prokaryotes that require Cbl cannot synthesize the molecule, and hence depend on uptake ([@bib21]; [@bib40]). For some microbial communities, for instance in the Ross Sea, it has been shown that Cbl production is the limiting factor for biomass production, which generates a demand for Cbl uptake systems among Cbl auxotrophs ([@bib7]).

In contrast to the well-characterized chemical properties of Cbl, as well as its biosynthesis and role in many enzymatic reactions, the uptake of the vitamin by bacteria is poorly understood. The only characterized Cbl uptake system is the *Escherichia coli* BtuCDF ATP binding cassette (ABC) transporter, which was first described in 1980 ([@bib13]). Substantial understanding of the system has been obtained through a combination of biochemical and structural studies ([@bib8]; [@bib20]; [@bib27]; [@bib28]; [@bib31]). The importer uses the periplasmic substrate-binding protein BtuF to capture Cbl or its precursor cobinamide (Cbi) with high affinity (K~d~ values of \~10 nM and \~40 nM, respectively) ([@bib10]; [@bib36]). Transport is powered by hydrolysis of ATP by the two BtuD subunits located on the cytoplasmic side of the membrane ([@bib9]). The substrate passes through the membrane at the interface between two copies of the transmembrane protein, BtuC ([@bib27]; [@bib28]). BtuCDF homologs are found widely in prokaryotes, but they are absent from a subset of bacteria that require uptake of vitamin B12 ([@bib39]).

An in silico study by [@bib39]) predicted that the energy coupling factor (ECF-) type ABC transporter ECF-CbrT might be a Cbl transporter ([@bib39]). ECF-transporters are multi-subunit membrane complexes that consist of two ATPases, similar to the ATPases of ABC transporters, and two membrane embedded proteins, not related to any other protein family ([@bib42]). The two ATPases and one of the transmembrane proteins, EcfT, form the 'energizing unit' or ' ECF-module'. The other membrane protein, termed S-component, acts as the substrate-binding protein and dynamically associates with the ECF-module to allow for substrate translocation. In so-called group II ECF transporters, multiple S-components specific for different substrates interact with the same ECF module ([@bib6]; [@bib23]; [@bib26]; [@bib32]; [@bib45]). For instance, in *Lactobacillus delbrueckii* eight different S-components are predicted to share a single ECF module, one of which, CbrT, was predicted to be specific for Cbl ([@bib39]; [@bib44]).

In this work, we biochemically and structurally characterize the ECF-CbrT complex from *L. delbrueckii*. We demonstrate that ECF-CbrT is a Cbl transporter that catalyses ATP-dependent uptake of Cbl and its precursor Cbi. We show that the S-component CbrT mediates high affinity substrate-specificity for Cbl and Cbi, and we report the crystal structure of ECF-CbrT from *L. delbrueckii* at 3.4 Å resolution in its *apo* inward-facing state. Although ECF-CbrT is structurally and mechanistically unrelated to BtuCDF, the kinetic parameters of the two transporters are very similar, suggestive of functional convergence.

Results {#s2}
=======

Expression of ECF-CbrT complements an *Escherichia coli* strain lacking its endogenous vitamin B12 transporter {#s2-1}
--------------------------------------------------------------------------------------------------------------

To demonstrate that ECF-CbrT is a vitamin B12 transporter, we constructed an *Escherichia coli* knock-out strain with three genomic deletions: Δ*btuF*, Δ*metE*, and Δ*btuC::Km^R^* (*E. coli* ΔFEC) ([@bib3]; [@bib11]; [@bib46]). A similar strain was previously used by [@bib10] to identify the substrate binding protein BtuF. The knock-out strain lacks the L-methionine synthase MetE ([@bib12]). *E. coli* possesses two L-methionine synthases, MetE and MetH. MetH uses Cbl as cofactor, whereas MetE is not dependent on the vitamin ([@bib4]; [@bib12]). Thus, deletion of *metE* makes *E. coli* dependent on Cbl for the synthesis of L-methionine. Because *btuF* and *btuC* are also deleted in *E. coli* ΔFEC, endogenous Cbl-uptake mediated by BtuCDF is abolished ([@bib10]), and (heterologous) expression of an active Cbl transporter is required to synthesize methionine.

We studied the growth of the deletion strain transformed with an expression plasmid for either BtuCDF (positive control), or an empty plasmid (negative control), or CbrT with or without the ECF module. We grew cells in 96-well plates using minimal medium supplemented with L-methionine or Cbl and monitored the optical density at 600 nm (OD~600~). In the presence of L-methionine, all strains grew readily, with a lag phase of 300--450 min ([Figure 2a--d](#fig2){ref-type="fig"}) ([@bib51]). The strains expressing BtuCDF or ECF-CbrT showed similar growth characteristics (lag time of 380 min and 470 min, respectively) in medium containing Cbl instead of L-methionine ([Figure 2a and c](#fig2){ref-type="fig"}, respectively), whereas the deletion strain expressing solitary CbrT (without its cognate ECF-module) did not show substantial growth in the absence of L-methionine when supplemented with Cbl ([Figure 2d](#fig2){ref-type="fig"}). The results demonstrate that the full ECF-CbrT complex constitutes a new Cbl transporter. ECF-CbrT also supported growth of *E. coli* ΔFEC in the presence of Cbi instead of Cbl, albeit with a longer lag-time (730 min) ([Figure 2c](#fig2){ref-type="fig"}), indicating that Cbi is a transported substrate of ECF-CbrT. We hypothesize that the longer lag time is due to the extra time required to express the necessary enzymes for Cbl synthesis from Cbi ([@bib30]). Our *in vitro* work shows that ECF- CbrT indeed supports efficient Cbl and Cbi transport (see below).

![ECF-CbrT supports cobalamin-dependent growth of an *E.coli* deletion strain.\
(**a**) The triple knock out strain *E. coli* ΔFEC expressing the BtuCDF ABC-transporter (positive control) grows in the presence of 50 μg/ml L-methionine or 1 nM CN-Cbl with lag-times of 300 min or 380 min, respectively, (**b**) *E. coli* ΔFEC carrying only the empty expression vector (negative control) grows only in the presence of 50 μg/ml L-methionine but not with 1 nM CN-Cbl. The lag-times of the negative controls are 450 min or \>1000 min, respectively. (**c**) *E. coli* ΔFEC expressing the entire ECF-CbrT transporter supports growth in the presence of either 1 nM Cbl or 1 nM Cbi with a lag-time of 470 min or 730 min, respectively. The lag-time in the presence of 50 μg/ml L-methionine is 410 min. (**d**) Expression of the solitary S-component CbrT without its cognate ECF-module is not able to support growth of *E. coli* ΔFEC in the presence of 1 nM CN-Cbl.](elife-35828-fig2){#fig2}

ECF-CbrT catalyzes ATP-dependent transport of cobalamin and cobinamide {#s2-2}
----------------------------------------------------------------------

We purified ECF-CbrT, reconstituted the complex in liposomes and assayed for the uptake of radiolabeled Cbl (^57^Co-cyanocobalamin). Uptake of radiolabeled Cbl into proteoliposomes was observed only when the proteoliposomes were loaded with Mg-ATP and not when Mg-ADP was incorporated ([Figure 3a](#fig3){ref-type="fig"}). While this experiment shows that transport is strictly ATP-dependent, similar to what was found for other ECF transporters ([@bib44]; [@bib45]), the ratio between ATP molecules hydrolyzed and Cbl molecules transported cannot be derived from this data. To obtain this ratio, simultaneous measurements of Cbl uptake and ATP hydrolysis rates are needed, which is technically difficult. Additionally, the related ECF transporter for folate displays a large extent of futile ATP hydrolysis (not coupled to transport \[[@bib44]\]), which further complicates the determination of the coupling ratio. Nonetheless, the EcfA and EcfA' subunits contain all the motifs to form functional ATPases, and therefore we speculate that transport of Cbl is coupled to the hydrolysis of two ATP molecules. Using an Mg-ATP concentration of 5 mM, the apparent K~M~ for Cbl uptake was 2.1 ± 0.4 nM and the V~max~ = 0.06 ± 0.01 nmol × mg^−1 ^× s^−1^ ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). To test the substrate specificity of the new vitamin B12 transporter, we conducted uptake experiments with a variety of competing compounds that are structurally similar to Cbl ([Figure 3b](#fig3){ref-type="fig"}). Addition of a 250-fold excess of unlabeled CN-Cbl inhibited the uptake of the radiolabeled substrate almost completely. Met-Cbl and OH-Cbl inhibited uptake to a similar extent as CN-Cbl, whereas Ado-Cbl was less effective (inhibition to \~25%). Addition of a 250-fold excess of Cbi also decreased the uptake of radiolabeled Cbl to \~25% ([Figure 3b](#fig3){ref-type="fig"}). To test whether Cbi is a transported substrate (that competitively inhibits transport of Cbl) or a non-transported compound that can only bind to the transporter, we directly measured uptake of Cbi ([Figure 3a](#fig3){ref-type="fig"}). Radiolabeled Cbi is not commercially available and, therefore, we synthesized the compound by treating ^57^Co-cyanocobalamin with perchloric acid (Schneider and Stroiński, 1987). The complete conversion of Cbl into Cbi was confirmed by mass spectrometry. Cbi was transported into liposomes containing ECF-CbrT, and transport required lumenal Mg-ATP, confirming that Cbi is a transported substrate ([Figure 3a](#fig3){ref-type="fig"}). Finally, we tested whether hemin inhibits Cbl transport ([Figure 3b](#fig3){ref-type="fig"}). Hemin and Cbl are structurally related and share the same precursor uroporphyrinogen-III ([@bib40]), but unlike Cbl, hemin consists of a flat porphyrin ring with a chelated iron ion, and has a chloride ion as one of the axial ligands. Hemin did not compete with Cbl-uptake ([Figure 3b](#fig3){ref-type="fig"}), showing that, although promiscuous among Cbl variants and Cbl-precursors, ECF-CbrT is a dedicated vitamin B12 transporter.

![^57^Co-cyanocobalamin (cyano-Cbl) and ^57^Co-cobinamide (Cbi) transport by purified and reconstituted ECF-CbrT.\
(**a**) ATP-dependent uptake of radiolabeled CN-Cbl and Cbi by ECF-CbrT in proteoliposomes. Proteoliposomes were loaded with either 5 mM Mg-ATP (circles for CN-Cbl, triangles for Cbi) or 5 mM Mg-ADP (CN-Cbl, squares). (**b**) Competition assay using Cbl-analogues. The initial uptake rate at 1 nM ^57^Co-cyanocobalamin (CN-Cbl) was measured. Competing compounds (adenosyl-cobalamin (Ado-Cbl); methyl-cobalamin (CH~3~-Cbl); hydroxyl-cobalamin (OH-Cbl); cobinamide or hemin) were added at a concentration of 250 nM. The uptake was normalized to a condition without competitor (10 pmol\*mg^−1^\*min^−1^). Since hemin is not readily soluble in an aqueous solution, we added 1% (v/v) DMSO during the assay, which did not affect the transporter activity. All competition experiments were performed in triplicate and the error bars indicate the standard deviation (s.d.).](elife-35828-fig3){#fig3}

We aimed to obtain further biochemical information on the solitary S-component CbrT. We could purify CbrT only in the substrate-bound state ([Figure 4a](#fig4){ref-type="fig"}). The protein without substrate was unstable in detergent solution and prone to aggregation. Apparently, substrate binding had a stabilizing effect on CbrT, an observation that has been made more often for membrane proteins ([@bib6]; [@bib45]).

![Cobalamin and cobinamide binding to CbrT.\
(**a**) Co-purification of CN-cobalamin with CbrT. The elution peak of the size exclusion column at a volume of 14 ml contains purified CbrT. The protein absorbs at 280 nm and CN-Cbl at 361 nm, showing that CbrT is eluted bound to CN-Cbl. (**b**) and (**c**) ITC measurements of Cbl and Cbi binding to CbrT. The determined *K~d~* values for Cbl and Cbi were averaged from triplicate measurements and the error is s.d. (**d**) ITC measurement showing the absence of Cbl-binding to the full complex, ECF-CbrT. Fitting of single binding site models to the data is shown in panel (**e**).](elife-35828-fig4){#fig4}

From the spectral properties of Cbl that was co-purified with CbrT, we conclude that CbrT binds Cbl in a \~ 1:1 ratio in detergent solution ([Figure 4a](#fig4){ref-type="fig"}), which reflects the common substrate to protein stoichiometry for S-components ([@bib6]; [@bib15]; [@bib44]). Because we could not obtain purified *apo* CbrT, we studied the substrate-binding affinity using *E. coli* crude membrane vesicles (CMVs) containing overexpressed *apo* CbrT. Isothermal titration calorimetry (ITC) revealed binding of both CN-Cbl and Cbi with dissociation constants of 9.2 ± 4.5 nM and 36 ± 15 nM, respectively ([Figure 4b,c and e](#fig4){ref-type="fig"}). As a negative control, CMVs without CbrT were used to exclude unspecific binding of CN-Cbl or Cbi ([Figure 4d](#fig4){ref-type="fig"}). Cbl analogues, OH-Cbl and Met-Cbl, were also probed with ITC and found to bind to CbrT with the similar binding affinities as CN-Cbl (K~d~ values of 9.6 ± 6.9 nM or 4.5 ± 0.3 nM, respectively, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), supporting the notion that CbrT is promiscuous towards the β-axial ligand of Cbl and corroborating the findings of the competition assay.

Although the use of crude membrane vesicles precluded the determination of the number of binding sites (the concentration of CbrT in the membrane vesicles is unknown), the thermodynamic values (*K~d~, ΔH* and *ΔS*) derived from the ITC measurements do not depend on this number. Assuming that CbrT has a single substrate binding site (consistent with the spectral properties, [Figure 4a](#fig4){ref-type="fig"}), the expression level of CbrT in the membranes could be calculated and we found that CbrT accounted for \~0.9% (w/w) of the protein content in the membrane.

Structure of the vitamin B12-specific ECF transporter in its *apo* and post substrate-release state {#s2-3}
---------------------------------------------------------------------------------------------------

We crystallized the ECF-CbrT complex in detergent (n-Dodecyl-β-D-maltopyranoside, DDM) solution and solved a crystal structure to 3.4 Å resolution using molecular replacement with the structure of the folate transporter, ECF-FolT2, from *L. delbrueckii* as a search model ([Figure 5a](#fig5){ref-type="fig"}) ([@bib44]). Statistics of data collection and structure refinement are summarized in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. There are two copies of ECF-CbrT in the asymmetric unit, corresponding to molecules A and B, each of them comprising CbrT, EcfT, EcfA and EcfA'.

![Comparison of the structures of ECF-CbrT and ECF-FolT from *L.delbrueckii*.\
(**a**) Cartoon representation of ECF--CbrT from the perspective of the plane of the membrane. Cytoplasmic ATPases, EcfA and EcfA', are colored in red, EcfT in cyan and CbrT in yellow. (**b**) Structural differences between the membrane domains of EcfT. The structures of ECF-CbrT (cyan) and ECF-FolT2 (green) from *L. delbrueckii* were superimposed by structural alignment of the ATPase units. Pro71 of EcfT is represented in sticks. (**c**) and (**d**) Surface representation of CbrT (**c**, yellow) and FolT2 (**d**, orange) interacting with EcfT (cartoon representation coloured in grey) with loop 3 of the S-components colored in blue. A dashed line highlights the movement of transmembrane helix 3 of EcfT. (**e**) and (**f**) Loop 3 obstructs access to the substrate binding cavity in CbrT but not in FolT2. (**e**) Slice-through of CbrT in surface representation, viewed from the plane of the membrane. Loop 3 is colored in blue. The ECF module has been omitted for clarity. (**f**) Same slice through representation like in (**e**) but for FolT2.](elife-35828-fig5){#fig5}

The identical ECF modules of the ECF-FolT2 and ECF-CbrT complexes have very similar overall structures, with a few notable conformational differences ([Figure 5b](#fig5){ref-type="fig"}). In both complexes, the two nucleotide-binding domains (NBDs; EcfA and EcfA') are in a nucleotide-free state, adopting an open conformation with two incomplete ATP-binding sites. With the NBDs of ECF-FolT2 and ECF-CbrT aligned structurally (rmsd 1.8 Å), the coupling helices of EcfT, which transmit the conformational changes of the NBDs upon ATP-hydrolysis to the membrane domains, also superimpose well between the two complexes (rmsd 1.5 Å). However, the transmembrane-helices of EcfT adopt different conformations (rmsd 4.4 Å). They are offset like rigid bodies, hinging approximately around Pro71 ([Figure 5b](#fig5){ref-type="fig"}). Structural flexibility of the membrane domain has been observed before ([@bib44]; [@bib50]) and is likely necessary to accommodate different S-components, and may facilitate toppling of the S-components during the catalytic cycle ([@bib44]).

The S-components CbrT and FolT2, which interact with the same ECF module in *L. delbrueckii*, do not share significant sequence similarity (16% identical residues). Accordingly, the structures show pronounced differences (rmsd 3.1 Å), although the overall folds are the same. Particularly, differences in loop 3 and loop 5 cause alterations of the protein surfaces that interact with the membrane domain of EcfT ([Figure 5c,d](#fig5){ref-type="fig"}). Therefore, tight association of the different S-components with the same ECF module requires the conformational adaptations in the membrane domain of the interacting EcfT subunits ([Figure 5c,d](#fig5){ref-type="fig"}).

CbrT is in a 'toppled' orientation in the ECF-CbrT complex with TMs 1, 2, 3 and 4 oriented almost parallel to the membrane plane. Although OH-Cbl was added in excess to the crystallization condition, the substrate was not bound. The *apo*-state of the toppled S-component was observed before in other ECF-type transporters and likely represents the inward-facing state after substrate release ([@bib44]; [@bib47]; [@bib49]; [@bib50]). The absence of substrate is in agreement with the proposed transport model, in that the inward oriented *apo* protein is a low affinity state ([@bib44]). It has been hypothesized that this state precedes ATP hydrolysis, which leads to release of the S-component from the ECF module and reorientation of the S-component in the membrane, which brings the substrate binding site back to the extracellular side ([@bib44]).

We hypothesize that the binding site for Cbl is located in a large cavity observed in the CbrT structure. The location of the cavity matches the position of the substrate-binding sites in structurally characterized S-components in the substrate-bound state ([@bib6]; [@bib15]; [@bib44]). In contrast to ECF-FolT2 ([@bib44]), and structurally characterized ECF complexes from other organisms ([@bib47]; [@bib49]; [@bib50]), the binding cavity in ECF-CbrT is largely occluded, and not accessible from the cytosol ([Figure 5e,f](#fig5){ref-type="fig"}). The occlusion is caused mainly by the position of loop 3, which obstructs access to the cavity in CbrT. We speculate that occlusion of the empty binding site after cytoplasmic release of the substrate may be required for the subsequent reorientation of the S-component, upon release from the ECF module.

Discussion {#s3}
==========

Comparative genomics studies have identified a wide range of ECF transporter families along with their putative substrate specificities mediated by their S-components ([@bib39]). Based on its genetic organization and the lack of a BtuCDF transporter homolog in the *Lactobacillales* genomes, CbrT was predicted to be a vitamin B12-specific S-component ([@bib39]). In *L. delbrueckii*, which was shown to be auxotrophic for vitamin B12 ([@bib29]), CbrT occurs within the *nrdJ--cbrS--cbrT--pduO* gene cluster. This genetic organization strongly implies an involvement of the substrate-binding protein CbrT in Cbl uptake: First, *nrdJ* is annotated as an adenosylcobalamin-dependent ribonucleotide reductase requiring the vitamin as a co-factor. Second, PduO is a Cbl adenosyltransferase, which converts Cbl into Ado-Cbl making it accessible for NrdJ. We showed that ECF-CbrT not only transports Cbl, but also mediates uptake of Cbi ([Figure 3a](#fig3){ref-type="fig"}). Therefore *L. delbrueckii* is expected to have the genetic repertoire to synthesize Cbl using Cbi as a precursor. However, we could not find homologs of the enzymes CobS, CobU and CobT, which are known to convert Cbi into cobalamin in *E. coli* ([@bib30]). Possibly other proteins might functionally compensate for their absence, which was shown for the thiamin kinase YcfN, which could replace CobU in *Salmonella typhimurium* ([@bib37]). However, it is also possible that *L. delbrueckii* CbrT binds Cbi in a futile mannerin which case Cbi would be transported but not used as a substrate for any enzyme. Finally, predicted CbrT homologs in *Lactobacillales* display a high degree of sequence identity, ranging from 25% to 60% compared to *L. delbrueckii* CbrT. Thus, we hypothesize that these CbrT homologs share the same function and represent substrate binding proteins for both Cbl and Cbi.

Our results show that ECF-CbrT is a new vitamin B12 transporter that is able to restore Cbl- and Cbi-dependent growth in *E. coli* ΔFEC ([Figure 2c](#fig2){ref-type="fig"}). Further characterization using uptake experiments with the purified ECF-CbrT complex ([Figure 3a](#fig3){ref-type="fig"}) and binding studies on CbrT show that the transporter is promiscuous towards the β-ligand of Cbl and also accepts Cbi as substrate ([Figure 3b](#fig3){ref-type="fig"}). A similar behavior has also been observed for BtuCDF ([@bib36]).

All three naturally occurring Cbl variants, OH-Cbl, Ado-Cbl and Met-Cbl, inhibit uptake of radiolabeled cyano-Cbl ([Figure 3b](#fig3){ref-type="fig"}). Whereas almost full inhibition was observed by a 250-fold excess of OH-Cbl, CN-Cbl, and Met-Cbl, Ado-Cbl inhibited only to 25%. This might be due to its bulkier β-ligand and a consequent steric hindrance. Nonetheless, the assay shows that ECF-CbrT is promiscuous toward the β-axial ligand of vitamin B12. Generally, poly-specificity to Cbl (and Cbl-derivatives, see below) and Cbi seems to be an inherent feature of vitamin B12 binding proteins, which is the case for BtuF, human Cbl-carriers, and also CbrT ([@bib16]; [@bib36]). In the human Cbl-carriers that share a similar promiscuity, the β-ligand side of the bound substrate is partially solvent exposed ([@bib17]; [@bib33]; [@bib48]). In CbrT, the broader substrate specificity might be related to flexibility of loops 1 and 3 that are the gates of CbrT and would make contact with the varying β-axial ligands.

In other ECF-transporters, the S-components exhibit remarkable high affinities toward their respective substrates with K~d~ values in the low nanomolar range ([@bib42]). ITC measurements with CbrT in the absence of the ECF module also show high-affinity binding of CN-Cbl, OH-Cbl, Met-Cbl, and Cbi ([Figure 4b,c and e](#fig4){ref-type="fig"}). The slightly lower affinity for Cbi (4-fold) is probably due to the lack of the α-igand ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) that leads to fewer possible protein-substrate interactions.

Strikingly, the affinity binding constants for CN-Cbl and Cbi are in the same range as the respective affinities determined for BtuF (Cbl of 9.1 nM and Cbi of 40 nM) ([@bib36]), which might imply that Cbl-transporters evolved to acquire the substrates with similar efficiency. Together with our *V~max~* and *K~M~* ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}) determination, we additionally show that the rate limiting step is substrate translocation, which means that the observed affinities are probably optimized for efficient substrate scavenging, followed by a slow translocation step. Human carriers achieve even higher affinities for Cbl (in the sub-picomolar range) ([@bib16]), but in these cases, the *off* rate is practically zero and substrate release requires proteolysis, which is not the mechanism of (ABC-) transporters.

Although it was already known for a long time that a plethora of uncharacterized prokaryotic vitamin B12 uptake systems must exist, only the BtuCDF complex had been extensively characterized. This is somewhat surprising, considering the potential relevance of bacterial vitamin B12 transport for pharmaceutical applications. For instance, given the increase in antibiotic resistance and its serious threat to public health ([@bib2]), it is imperative to find and characterize novel protein targets for drug design. Several pathogenic bacteria, such as *Streptoccoccus pyogenes* and *Clostridium tetani*, carry a *cbrT* gene, lack a BtuCDF homolog, and are Cbl-auxotrophs, which makes them strictly dependent on dedicated transporters to scavenge either vitamin B12 or its precursors from the environment. Because humans use endocytosis to take up Cbl ([@bib38]), Cbl-specific prokaryotic transporters are potential drug targets for vitamin B12 auxotrophic pathogens.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\         Designation                     Source or reference           Identifiers                        Additional information
  or resource                                                                                                                      
  ------------------------------- ------------------------------- ----------------------------- ---------------------------------- ---------------------------------------------
  Gene\                           cbrT                            NA                            LDB_RS00385                        
  (*Lactobacillus delbrueckii*\                                                                                                    
  subsp. *bulgaricus*)                                                                                                             

  Strain, strain\                 MC1061                          Casadaban, M. J., and\                                           E. coli ΔFEC was constructed in\
  background (*E. coli*)                                          Cohen, S. N. (1980).\                                            this paper with the following\
                                                                  Analysis of gene control\                                        deletions ΔbtuF, ΔmetE, and ΔbtuC::\
                                                                  signals by DNAfusion\                                            KmR. Strain requires either L-methionine\
                                                                  and cloning in Escherichia\                                      or cobalmin/cobinamide plus expression\
                                                                  coli.Journal of Molecular\                                       of an appropiate cobalmin/cobinamide\
                                                                  Biology, 138(2),179--207\                                        transporter. Strain can be made available\
                                                                  PMID 6997493                                                     upon reasonable request.

  Strain, strain\                 JW0154                          Coli Genetic Stock\                                              E. coli ΔFEC was constructed in this\
  background (*E. coli*)                                          Center Yale                                                      paper with the following deletions\
                                                                                                                                   ΔbtuF, ΔmetE, and ΔbtuC::KmR. Strain\
                                                                                                                                   requires either L-methionine or\
                                                                                                                                   cobalmin/cobinamide plus expression\
                                                                                                                                   of an appropiate cobalmin/cobinamide\
                                                                                                                                   transporter. Strain can be made available\
                                                                                                                                   upon reasonable request.

  Strain, strain\                 JW3805                          Coli Genetic Stock\                                              E. coli ΔFEC was constructed in this\
  background (*E. coli*)                                          Center Yale                                                      paper with the following deletions ΔbtuF,\
                                                                                                                                   ΔmetE, and ΔbtuC::KmR. Strain requires\
                                                                                                                                   either L-methionine or cobalmin/cobinamide\
                                                                                                                                   plus expression of an appropiate cobalmin/\
                                                                                                                                   cobinamide transporter. Strain can be\
                                                                                                                                   made available upon reasonable request.

  Strain, strain\                 JW1701                          Coli Genetic Stock\                                              E. coli ΔFEC was constructed in this paper\
  background (*E. coli*)                                          Center Yale                                                      with the following deletions ΔbtuF, ΔmetE,\
                                                                                                                                   and ΔbtuC::KmR. Strain requires either\
                                                                                                                                   L-methionine or cobalmin/cobinamide\
                                                                                                                                   plus expression of an appropiate cobalmin/\
                                                                                                                                   cobinamide transporter. Strain can be\
                                                                                                                                   made available upon reasonable request.

  Strain, strain\                 ΔFEC                            This paper                                                       E. coli ΔFEC was constructed in this paper\
  background (*E. coli*)                                                                                                           with the following deletions ΔbtuF, ΔmetE,\
                                                                                                                                   and ΔbtuC::KmR. Strain requires either\
                                                                                                                                   L-methionine or cobalmin/cobinamide\
                                                                                                                                   plus expression of an appropiate cobalmin/\
                                                                                                                                   cobinamide transporter. Strain can be\
                                                                                                                                   made available upon reasonable request.

  Biological sample\              Lactobacillus delbrueckii\      DSMZ                          DSM 20081                          
  (*Lactobacillus delbrueckii*)   subsp. bulgaricus genomic DNA                                                                    

  Recombinant\                    pBAD24_CbrT                     This paper                                                       Expression plasmids for CbrT and\
  DNA reagent                                                                                                                      ECF-CbrT in *E. coli*. Plasmids can be\
                                                                                                                                   provided upon reasonable request.

  Recombinant\                    p2BAD_ECF_CbrT                  This paper                                                       Expression plasmids for CbrT and\
  DNA reagent                                                                                                                      ECF-CbrT in *E. coli*. Plasmids can be\
                                                                                                                                   provided upon reasonable request.

  Chemical\                       CN-Cbl                          Acros                         405920050                          
  compound, drug                                                                                                                   

  Chemical\                       OH-Cbl                          Sigma-Aldrich                 95200--1G                          
  compound, drug                                                                                                                   

  Chemical\                       Met-Cbl                         Sigma-Aldrich                 M9756-250G                         
  compound, drug                                                                                                                   

  Chemical\                       Ado-Cbl                         Sigma-Aldrich                 C0884-250MG                        
  compound, drug                                                                                                                   

  Chemical\                       Cbi                             Sigma-Aldrich                 C3021-50MG                         
  compound, drug                                                                                                                   

  Chemical\                       hemin                           Sigma-Aldrich                 51280--1G                          
  compound, drug                                                                                                                   

  Chemical\                       57Co-cyanocobalamin             MP-Biomedicals                06B-430000                         
  compound, drug                                                                                                                   

  Chemical\                       perchloric acid                 Sigma-Aldrich                 311421--50 ML                      
  compound, drug                                                                                                                   

  Software,\                      Origin 8                        Company                                                          
  algorithm                                                                                                                        

  Other                           ECF-CbrT coordinate file\       this paper                    accession numberPDB ID code 6FNP   Crystal structure of ECF-CbrT
                                  and structure factors                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Molecular methods {#s4-1}
-----------------

For expression, CbrT (LDB_RS00385) was amplified by means of polymerase chain reaction (PCR) using *L. delbrueckii* subsp. *bulgaricus* genomic DNA as a template. For expression of the entire complex, CbrT was inserted into the second multiple cloning site of p2BAD_ECF ([@bib44]) with *XbaI* and *XhoI* restriction sites. For expression of solitary CbrT, the gene was inserted with a C-terminal octa-His-tag into pBAD24 ([@bib22]) using *NcoI* and *HindIII* restriction sites. A single glycine (Gly2) was introduced to be in-frame with the start-codon of the *NcoI* restriction site, which is not present in the full complex. All primers used are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"} and all sequences were checked for correctness by sequencing.

Expression and membrane vesicle preparation {#s4-2}
-------------------------------------------

ECF--CbrT was expressed as described previously ([@bib44]) with the following adaptations; plain Luria Miller broth (LB) medium was used and the growth temperature was kept constant at 37°C throughout. After 3 hr of expression, the cells were harvested by centrifugation (20 min, 7,446 × g, 4°C) and resuspended in 50 mM KPi, pH 7.5. Cells were either immediately used for membrane vesicles preparation or the resuspended cells were flash frozen in liquid nitrogen and stored at −80°C until use. Membrane vesicles were prepared as previously described ([@bib44])

ECF-CbrT purification {#s4-3}
---------------------

Crude membrane vesicles containing ECF-CbrT were solubilized in buffer A (50 mM KPi, pH 7.5, 300 mM NaCl, 10% glycerol, 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace) for 45 min at 4°C under constant movement. Unsolubilized material was removed by centrifugation (35 min, 287,000 × g, 4°C), the supernatant was loaded on a BioRad PolyPrep column containing 0.5 mL Ni^2+-^sepharose bed volume (GE healthcare), pre-equilibrated with 20 column volumes (CV) buffer B (50 mM KPi, pH 7.5, 300 mM NaCl, 10% glycerol) and allowed to incubate for 1 hr at 4°C under constant movement. Unbound protein was allowed to flow through and the column was washed with 20 CV of buffer C (50 mM KPi, pH 7.5, 300 mM NaCl, 10% glycerol, 50 mM imidazole, 0.05% DDM). ECF--CbrT was eluted with buffer D (50 mM KPi, pH 7.5, 300 mM NaCl, 10% glycerol, 500 mM imidazole, 0.05% (w/v) DDM) in three fractions of 0.4 ml, 0.75 ml and 0.5 ml, respectively. ECF-CbrT eluted mostly in the second elution fraction that was loaded on a Superdex 200 Increase 10/300 gel filtration column (GE Healthcare) that was equilibrated with buffer E (50 mM Hepes pH 8, 150 mM NaCl, 0.05% DDM). For crystallization, ECF-CbrT was purified following the same protocol but buffers A to D contained 1% DDM. Buffers A to D were supplemented with 0.5 mM hydroxyl-cobalamin (OH-Cbl, Sigma Aldrich), and buffer E contained 10 μM OH-Cbl. For all experiments, the peak fractions were collected, combined and either used directly for reconstitution or concentrated in a Vivaspin disposable ultrafiltration device with a molecular weight cut-off of 30 kDa (Sartorius Stedim Biotech SA) to a final concentration of 6 mg\*ml^−1^.

Construction of the E. coli ΔFEC strain {#s4-4}
---------------------------------------

The *E. coli* strains JW0154 (*ΔbtuF::Km^R^*), JW3805(*ΔmetE::Km^R^*) and JW1701*(ΔbtuC::Km^R^*) from the Keio collection ([@bib3]) were purchased from the Coli Genetic Stock Center, Yale. *E. coli* JW0154 (*ΔbtuF::Km^R^*) was used as the basis for constructing *E. coli*ΔFEC. The kanamycin resistance cassette of JW0154 was removed using the FLP recombinase as described before ([@bib11]), resulting in *E. coli*ΔF. The *metE::Km^R^* locus from JW3805 was introduced in *E. coli*ΔF using P1-mediated generalized transduction as described ([@bib35]; [@bib46]), resulting in *E. coli*ΔFE*::Km^R^*. The kanamycin cassette was removed using the FLP recombinase, resulting in *E. coli*ΔFE. The *ΔbtuC::Km^R^* locus of JW1701 was introduced in *E. coli*ΔFE using P1-mediated generalized transduction, resulting in *E. coli*ΔFEC. Colony PCRs based on three primer pairs (*buF*-locus, 5'-atggctaagtcactgttcagg-3' and 5'-ctaatctacctgtgaaagcgc-3'; *butC*-locus, 5'-atgctgacacttgcccgc-3' and 5'-ctaacgtcctgcttttaacaataacc-3'; *metE*-locus, 5'-atgacaatattgaatcacaccctcg-3' and 5'-ttacccccgacgcaagttc-3') were used to verify *Km^R^*-insertions, the FLP-recombinase-mediated removal of Km^R^-markers and the absence of any genomic duplications resulting in the presence of any wild-type *metE*, *btuC* and *btuF* loci.

Growth assay with *E. coli* ΔFEC strains {#s4-5}
----------------------------------------

The strains carrying various expression vectors were grown overnight at 37°C on LB-agar plates supplemented with 25 μg\*ml^−1^ kanamycin and 100 μg\*ml^−1^ ampicillin. The composition of the M9-based (47.7 mM Na~2~HPO~4~\*12H~2~O, 17.2 mM KH~2~PO~4~, 18.7 mM NH~4~Cl, 8.6 mM NaCl) minimal medium was supplemented with 0.4% glycerol, 2 mM MgSO~4~, 0.1 mM CaCl~2~, 100 μg\*ml^−1^L-arginine, 25 μg\*ml^−1^ kanamycin and 100 μg\*ml^−1^ ampicillin. A single colony was picked and used to inoculate a 3 ml to 6 ml liquid pre-culture supplemented with 50 μg\*ml^−1^L-methionine (Sigma-Aldrich). The pre-culture was grown \~ 24 hr at 37°C, shaking in tubes with gas-permeable lids (Cellstar). The main cultures were inoculated in a 1:500 inoculation ratio. The main culture had a volume of 200 μl and was supplemented with 0.00001% L-arabinose (Sigma-Aldrich) and either 50 μg\*ml^−1 ^L-methionine, 1 nM dicyano-cobinamide (Sigma Aldrich), or 1 nM cyano-cobalamin (Acros Organics). The medium was added to a sterile 96 well-plate (Cellstar). The 96-well plate was sealed with a sterile and gas-permeable foil (BreatheEasy, Diversified Biotech). The cultures were grown for 1000 min in a BioTek Power Wave 340 plate reader at 37°C, shaking. The OD~600~ was measured every five minutes at 600 nm. All experiments were conducted as technical triplicates from biological triplicate. To obtain lag-times the averaged growth curves were fitted with the Gompertz-fit in Origin eight and further analyzed as described ([@bib51]).

Crystallization and structure determination {#s4-6}
-------------------------------------------

Initial crystallization conditions for ECF-CbrT were screened at 4°C using commercial sparse-matrix crystallization screens in a sitting-drop setup and a Mosquito robot (TTP Labtech, UK). Initial crystals were found in the B11 condition (0.2 M KCl, 0.1 M Sodium citrate, pH 5.5, 37% (v/v) Pentaerythritol propoxylate (5/4 PO/OH)) of the MemGold1 HT-96 screen (Molecular Dimensions, UK) that diffracted up to 7.5 Å resolution. Using this condition as a starting point and the detergent (HR2-408) screen (Hampton Research, USA), an optimized condition could be found and contained the detergent ANAPOE^®^-C~12~E~10~ (Polyoxyethylene(10)dodecyl ether, Hampton Research) as an additive, which yielded crystals diffracting up to 3.4 Å resolution.

X-ray diffraction data were collected from cooled (100 K) single crystals at synchrotron beam lines at the Swiss Light Source (SLS) beamline PXI, Switzerland. The crystals of *apo* ECF--CbrT belong to space group P1 (unit cell parameters: a = 85.47, b = 92.86, c = 105.51, α = 72.568, β = 66.274, γ = 62.893).

To correct for anisotropy, the dataset was treated at the diffraction anisotropy server prior to further processing ([@bib43]). Data were processed with XDS ([@bib25]) and scaled with Xscale ([@bib24]). Data collection statistics are summarized in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. The structure of the ECF-CbrT complex was solved by molecular replacement with PHASER MR ([@bib34]) using the *apo* ECF-FolT structure of *L. delbrueckii* ([@bib44]) (PDB code 5JSZ) as a search model. For model completion, several cycles of model building with COOT ([@bib14]) and refinement with PHENIX ([@bib1]) were performed. The Ramachandran statistics are 72.32% for favoured regions, 26.64% for allowed regions and 1.05% for outliers. All structural figures in the main text were prepared with an open-source version of pymol (<https://sourceforge.net/projects/pymol/>).

Preparation of radiolabeled cobinamide from radiolabeled cobalamin {#s4-7}
------------------------------------------------------------------

The required amount of cyano-cobalamin (radiolabeled and unlabeled) was mixed in a 1:1 (v/v) ratio with 70% perchloric acid (Sigma-Aldrich) and incubated for ten minutes at 70°C. To quench the reaction and prevent damage to the substrate, the resulting cobinamide substrate was added to buffer G (as described above), which was additionally supplemented with 5 M NaOH to restore the pH back to 7.5.

Radiolabeled vitamin B12 transport assay {#s4-8}
----------------------------------------

Purified ECF-CbrT was reconstituted in proteoliposomes as described previously ([@bib18]). Proteoliposomes were thawed and loaded with 5 mM MgSO~4~ or MgCl~2~ and 5 mM Na~2~-ATP or Na~2~-ADP through three freeze-thaw cycles. Loaded proteoliposomes were extruded nine times through a polycarbonate filter with a 400 nm pore-size (Avestin), pelleted by centrifugation (267,008 g, 35 min, 4°C) and resuspended in buffer F (50 mM KPi pH 7.5) to 2 μl\*mg^−1^ lipids. The uptake reaction was started by addition of concentrated and loaded proteoliposomes to buffer G (50 mM KPi pH 7.5, varying concentrations of ^57^Co-cyanocobalamin (150 to 300 μCi\*mg^−1^, in 0.9% benzylalcohol, MP Biomedicals) in a 1:100 ratio. At elsewhere specified time points 200 μl samples were taken transferred into 2 ml ice cold buffer F and filtered over OE67 cellulose acetate filters (GE Healthcare) soaked in Buffer F supplemented with cyanocobalamin (Acros chemicals). The filter was washed with 2 ml ice cold buffer F and transport of radiolabeled substrate was counted in Perkin Elmer Packard Cobra II gamma counter. All uptake assays were performed at 30°C while stirring.

Substrate-binding assay by isothermal thermal calorimetry (ITC) {#s4-9}
---------------------------------------------------------------

ITC measurements were performed using a NanoITC calorimeter (TA Instruments) at 25°C. Membrane vesicles containing CbrT (200 μl, 10 mg\*ml^−1^ in 50 mM KPi, pH 7.5) were added to the NanoITC cell. Ligands were prepared in 50 mM KPi, pH 7.5 and titrated into the cell in 1 μl injections with 140 s between each injection. Membrane vesicles containing the full-complex ECF-CbrT that does not bind CN-Cbl (10 mg\*ml^−1^ in 50 mM Kpi, pH 7.5) were used as a negative control. Data were analyzed with the Nano Analyze Software.

Data deposition {#s4-10}
---------------

The atomic coordinates and structure factors have been deposited in the Protein Data Bank, [www.pdb.org](http://www.pdb.org) (PDB ID code 6FNP).
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Data availability {#s7}
-----------------

Diffraction data have been deposited in PDB under the accession code 6FNP.

The following dataset was generated:

Slotboom D2018Diffraction data from: Functional and structural characterization of an ECF-type ABC transporter for vitamin B12<http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FNP>Publicly available at the RCSB Protein Data Bank (accession no: 6FNP)

10.7554/eLife.35828.016

Decision letter

Faraldo-Gómez

José D

Reviewing Editor
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Functional and structural characterization of an ECF-type ABC transporter for vitamin B12\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ming Zhou (Reviewer \#2); Douglas C Rees (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Santos et al. describes a functional and structural characterization of an ECF-type ABC transporter for vitamin B12. ECF-type ABC transporters are a relatively recent addition to the ABC transporter family and consist of two ATPases similar to the ATPases of ABC transporters, with two transmembrane subunits -- an ECF-module (energizing/transduction) and an S-component (substrate binding module). An interesting feature is that multiple S-components can interact with a single ECF module. Contributions of this paper include the demonstration that ECF-CbrT functions as a B12 transporter (by complementing an *E. coli* strain lacking the endogenous BtuCDF system (itself an ABC transporter); that ECF-CbrT catalyzes the ATP-dependent transport of B12 derivatives (by transport assays in reconstituted liposomes); that B12 derivatives binding to CbrT with nM affinities; and by determining the crystal structure of ECF-CbrT to 3.4 A resolution in a state likely corresponding to the apo, post-substrate release state. Comparison of this structure to ECF-FolT folate transporter establishes how different S-components interact with the same ECF-module. Together these studies provide a detailed characterization of a newly identified transport system for vitamin B12.

The experimental studies appear to have been carefully conducted, and are generally well documented. The crystal structure and the functional data are of good quality. This study therefore represents an important advance in our understanding of the mechanism of ECF transporters and ABC transporters generally.

Essential revisions:

1\) It is not immediately clear how the protein concentration was calibrated in the ITC experiments using the crude membrane vesicles, and how uncertainties in this parameter might influence the thermodynamic data. Please clarify.

2\) Please discuss what you propose for the ratio of ATP hydrolyzed to ligand transported, and the basis for that proposal. If feasible, can this stoichiometry be determined from experiments such as those depicted in Figure 3?
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Author response

> Essential revisions:
>
> 1\) It is not immediately clear how the protein concentration was calibrated in the ITC experiments using the crude membrane vesicles, and how uncertainties in this parameter might influence the thermodynamic data. Please clarify.

We now clarify these points in the text:

"Although the use of crude membrane vesicles precluded the determination of the number of binding sites (the concentration of CbrT in the membrane vesicles is unknown), the thermodynamic values (*Kd, ΔH* and *ΔS*) derived from the ITC measurements do not depend on this number. Assuming that CbrT has a single substrate binding site (consistent with the spectral properties, Figure 4A), the expression level of CbrT in the membranes could be calculated and we found that CbrT accounted for \~0.9% (w/w) of the protein content in the membrane."

> 2\) Please discuss what you propose for the ratio of ATP hydrolyzed to ligand transported, and the basis for that proposal. If feasible, can this stoichiometry be determined from experiments such as those depicted in Figure 3?

We added the following text:

"While this experiment shows that transport is strictly ATP- dependent, similar to what was found for other ECF transporters (Swier et al., 2016; ter Beek et al., 2011a), the ratio between ATP molecules hydrolysed and Cbl molecules transported cannot be derived from this data. \[...\] Nonetheless, the EcfA and EcfA' subunits contain all the motifs to form functional ATPases, and therefore we speculate that transport of Cbl is coupled to the hydrolysis of two ATP molecules."
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